Life Sciences Voice

GSK has secured U.S. approval for bepirovirsen, an antisense oligonucleotide licensed from Ionis Pharmaceuticals, marking a milestone in the treatment of chronic hepatitis B. Marketed as Hibsago, the medicine introduces an antisense-based approach to t...

Pharmaceutical commercial teams are operating in markets where competitive activity, treatment preferences, access conditions, and customer expectations can change quickly. Traditional commercial intelligence often relies on perio...

Artificial intelligence is reshaping drug discovery, clinical development, manufacturing, regulatory operations, and Medical Affairs. As adoption expands, life sciences leaders must determine where AI can deliver meaningful...

Digital therapeutics (DTx) are evolving beyond standalone software interventions toward more personalized, connected, and clinically integrated treatment experiences. Early digital therapeutics demonstrated how software could deliver structured interventions for conditions such as diabetes, insomnia, and substance use disorders. The next phase is expa...

Disc Medicine has reported that its experimental drug bitopertin met all primary and secondary endpoints in a phase 3 trial involving patients with erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder that causes painful reactions to sunlight. The findings include a reduction in a disease-associated blood biomarker and an increase in the time patients coul...